Arginase: An emerging and promising therapeutic target for cancer treatment

Biomed Pharmacother. 2022 May:149:112840. doi: 10.1016/j.biopha.2022.112840. Epub 2022 Mar 19.

Abstract

Arginase is a key hydrolase in the urea cycle that hydrolyses L-arginine to urea and L-ornithine. Increasing number of studies in recent years demonstrate that two mammalian arginase isoforms, arginase 1 (ARG1) and arginase 2 (ARG2), were aberrantly upregulated in various types of cancers, and played crucial roles in the regulation of tumor growth and metastasis through various mechanisms such as regulating L-arginine metabolism, influencing tumor immune microenvironment, etc. Thus, arginase receives increasing focus as an attractive target for cancer therapy. In this review, we provide a comprehensive overview of the physiological and biological roles of arginase in a variety of cancers, and shed light on the underlying mechanisms of arginase mediating cancer cells growth and development, as well as summarize the recent clinical research advances of targeting arginase for cancer therapy.

Keywords: Arginase; Cancer; Inhibitors; L-arginine; Mechanism; Therapeutic target.

Publication types

  • Review

MeSH terms

  • Animals
  • Arginase* / metabolism
  • Arginine / metabolism
  • Mammals
  • Neoplasms* / drug therapy
  • Tumor Microenvironment
  • Urea

Substances

  • Urea
  • Arginine
  • Arginase